AbbVie (ABBV) has an average broker rating of 2.27, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
AbbVie (ABBV) stock is expected to deviate a maximum of $10.61 from the average target price of $72.57 for the short term period. 14 Street Experts have initiated coverage on the stock with the most promising target being $90 and the most muted being $47.
Also, Equity Analysts at the Brokerage Firm, JP Morgan, downgrades their rating on the shares of AbbVie (NYSE:ABBV). JP Morgan has a Neutral rating on the shares. Previously, the analysts had a Overweight rating on the shares. The rating by the firm was issued on September 8, 2016.
AbbVie (NYSE:ABBV): After opening at $63.17, the stock dipped to an intraday low of $62.92 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $63.82 and the buying power remained strong till the end. The stock closed at $63.35 for the day, a gain of 0.02% for the day session. The total traded volume was 7,811,582. The stocks close on the previous trading day was $63.34.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.